Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of Information, Enhanced heparanase expression correlates with metastatic potential; tumor vascularity and reduced postoperative survival of cancer patients. These observations, the anti-cancerous effect of heparanase gene silencing (ribozyme, siRNA) and of heparanase-inhibiting oligosaccharides, peptides and antibodies, as well as the unexpected identification of a single functional heparanase, suggest that the enzyme is a promising target for anti-cancer drug development. Our studies focused on the regulation of heparanase gene expression (i.e., promoter methylation, action of sex steroids, p53) and effect of augmented levels the enzyme on malignant behavior of prostate cancer cells. We designed effective inhibitory strategies, based on recently created chemical and molecular tools (chemically modified heparin species, siRNA-expressing vector), as well as on better understanding of biochemical aspects of heparanase proenzyme activations (inhibitory peptide approach), toward future development of effective anti-cancer therapeutic modalities.
HS proteoglycans (HSPGs) and HS-degrading enzymes have long been implicated in a number of cancer-and angiogenesis-related cellular events, including cell invasion, migration, adhesion, differentiation and proliferation (1, 2) . It appears that apart of direct involvement in basement membrane (BM) invasion by tumor and endothelial cells, heparanase elicits an indirect growth-promoting response by releasing HS-bound growth factors (i.e., bFGF, VEGF) from the extracellular matrix and BM, and by generating HS fragments which can potentiate bFGF receptor binding, dimerization and signaling (2) . A significant correlation was found between heparanase mRNA expression and tumor vascularity in cancer patients (3) . Expression of heparanase correlates with the metastatic potential of human tumor cells (1, 4, 5) . Moreover, elevated levels of heparanase were detected in the urine of patients with aggressive metastatic disease. Evidence for a direct role of heparanase in tumor metastasis was provided by the increased lung and liver colonization of cancer cells following transfection and overexpression of the heparanase gene (6) . Non-anticoagulant and chemically modified species of heparin and laminaran sulfate which inhibited tumor cell heparanase, also inhibited experimental metastasis (7).
These observations, as well as preferential expression of heparanase in human prostate carcinoma ( Fig. 1) , suggest that the enzyme is causally involved in prostate cancer progression and might be a promising target for anti-cancer drug development. Our studies, described in this report, are aimed to elucidate the significance of heparanase in prostate tumorigenesis and to develop heparanase-targeting inhibitory strategies that will suppress primary growth, angiogenesis and metastasis of prostate cancer.
BODY.
1. Heparanase over-expression and prostate cancer progression.
a. Preferential expression of heparanase in primary human prostate tumors and their lymphnode and bone metastases has been demonstrated in our previous experiments (as outlined in the original application). In continuation of this study, heparanase expression was investigated in 35 cases of prostate cancer and correlated with clinical data on progression of the disease. Intense staining of heparanase was found in 21% of patients with biochemical failure (i.e., rise in PSA levels) detected 3-5 years after resection of the primary tumor, as compared to 6% of patients that showed no evidence of disease (Fig. 1 ).
These results indicate that heparanase may be applied as a prognostic marker of prostate cancer progression.
b. Transgenic mice over-expressing heparanase (8) were cross-mated with TRAMP mice.
Mice positive for both genes were identified by PCR using primers specific for TRAMP and heparanase. Only 5 double homozygous male mice were identified and all developed prostate tumors and dyed within 3-4 months after birth. TRAMP mice developed tumors at a much slower rate and survived for 8-12 months (Fig. 2) . The corresponding female mice were not affected. It appears that the heparanase-rich tumor microenvironment of the hpatransgenic mice supports tumor take, growth rate and metastasis, but the number of mice was too small and survival time too short for establishment of a double homozygous transgenic mice colony. Metastases formation was not evaluated, since only few mice were available and spared for establishment of a colony. Unfortunately, these mice dyed early and we were unable to obtain offspring. (Fig. 4 ). In contrast, there was no effect in AR-negative DU145 cells. Androgen treatment also induced a 3-4-fold increase in hpa-mRNA expression in CWR cells, confirming the promoter study data.
ii. Heparanase promoter activity is regulated by p53 in prostate cancer. Mutational inactivation of p53 is the most frequent genetic alteration in human cancers. To investigate whether heparanase gene expression is affected by p53, CWR prostate cancer cells were co-transfected with the reporter vector described above, and a pCDNA3 plasmid encoding the wt p53. Luciferase activity was determined 24 h later, revealing a marked decrease in transcriptional activity of the hpa-promoter and enzymatic activity of heparanase (Fig. 5 ).
These results indicate that heparanase gene expression in prostate cancer cells is upregulated upon inactivation of p53. In another set of experiments, we compared endogenous heparanase (hpa) expression in murine embryonic fibroblasts (MEF) derived from wt and p53 knock out (p53-) mice. Heparanase mRNA expression, assessed by semiquantitative reverse transcription polymerase chain reaction (RT-PCR), was markedly elevated in p53-MEF (Fig. 6A) . Moreover, heparanase enzymatic activity in cell lysates of p53--MEF was significantly higher as compared to wt MEF (Fig. 6B ). ii. Heparanase gene silencing averts tumor invasiveness, angiogenesis and metastatic spread. We employed gene-silencing strategies to demonstrate the contributory role of heparanase in malignancy and explored the therapeutic potential of its specific targeting. For this purpose, we designed plasmid vectors that enable effective expression of small interfering (si) RNA directed against the human and mouse (9) iii. Peptides and point mutations inhibiting heparanase proteloytic processing and activation. Peptides corresponding to the potential cleavage region were synthesized and tested for their ability to competitively inhibit the cleavage reaction. A synthetic peptide (LREHYQKKFKN) was found to inhibit processing and activation of the 65 kDa latent enzyme. An adjacent peptide (FDPKKESTFEERFDER) had no inhibitory effect. Proteolytic cleavage of the 65 kDa proenzyme occurs in two potential cleavage sites, Glu' 0 9 -Ser' 10 and Gln 157 -Lys 59 . In order to elucidate whether heparanase processing and activation involve two distinct sites and identify amino acids that are essential for heparanase processing, we introduced point mutations in each of the two potential cleavage sites and their adjacent amino acids. Heparanase negative cells (JAR human choriocarcinoma) were transfected with each of the point mutated full-length constructs and tested for heparanase processing (Western blotting) and enzymatic activity. Our results indicate that point mutations in site 2 and its vicinity affect heparanase processing as reflected by lack of processing (i.e., Q 157 ---K; Y 156---A) and lack of enzymatic activity in the hpa-transfected JAR cells. On the other hand, various point mutations and deletions in site 1 had no effect on heparanase processing and activation.
KEY RESEARCH ACCOMPLISHMENTS.
i) Heparanase has been characterized as a promising prognostic marker of prostate cancer progression.
ii) Causal involvement of heparanase in prostate tumorigenesis has been demonstrated in various in vivo systems (spontaneous tumor formation in transgenic mice, transplantable tumor models).
iii) We found that heparanase expression in prostate is tightly regulated at the level of promoter activity. In particular, testosterone and p53 have been identified as critical determinants of heparanase promoter induction/inhibition (in accordance).
iv) Several anti-heparanase inhibitory strategies were developed and tested:
-enzymatic inhibition approach: chemically modified species of heparin with increased heparanase-inhibiting ability but lacking other biological activities of normal heparin (i.e., anticoagulant, pro-angiogenic) that are irrelevant or undesirable in the case of anti-tumor drug development.
-gene-silencing approach: short inhibitory RNA (siRNA) characterized by increased stability and specificity of targeting.
-inhibition of proteolytic processing of pro-heparanase enzyme, based on precise characterization of its cleavage site(s).
REPORTABLE OUTCOMES.
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Meeting (Anaheim, California). Testosterone, nM was determined 24 h later and is expressed in Fraction relative light units. Fig. 6 . Increased heparanase expression in p53 knock out murine embryonic fibroblasts (MEF). A. Hpa) mRNA expression. RNA isolated from wt and p53-1-MEF, was reverse transcribed to cDNA and subjected to comparative semiquantitative PCR. Aliquots (10 jtl) of the PCR products were separated by 1.5% agarose gel electrophoresis and visualized. B. Enzymatic activity. MEF (lxI 06 cells), obtained from wt or p53 knock out (p53-1-) mice were tested for heparanase activity, as 
